General Discussions

Early Steroid Use Reduces Cytokine Release Syndrome Risk With Axi-Cel Treatment

Steroid use while cytokine release syndrome (CRS) and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurolog...

Finding Strength and Hope in the Midst of Breast Cancer Treatment

By Essie Roman, LMSW, Women's Clinic Program Coordinator, CancerCare Breast cancer is the second-most common cancer among American women, after skin cancer. Currently, the average risk of...

BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid Tumors

BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prio...

Expert Talks Liquid Biopsies, Molecular Testing in Lung Cancer

Not all patients with advanced non–small cell lung cancer (NSCLC) are recommended for genomic testing when treated in a community setting, and are therefore not being appropriately tested for...

Doing Favors for Patients

Oncology nurses should aspire to give care that goes above and beyond what is necessary to assure the safety and wellbeing of their patients. They are charged with reducing the suffering of patient...

Genetic Testing and Inherited Increased Risk of Cancer

By: Charlotte Ference, LMSW The American Cancer Society estimates that 5%-10% of cancers are connected with mutations in the DNA that are inherited through generations.1 For millions of patie...

After Doughnut Hole Closure, Oral Anticancer Drug Costs Still Too High for Many

Stacie Dusetzina, PhD Studies show that cost is a factor in patient adherence to their oral anticancer medications, but the financial burden of oral chemotherapy drugs is projected to still be to...

FDA Approves Alpelisib for Metastatic Breast Cancer

The FDA has approved the PI3K inhibitor alpelisib (Piqray) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast ca...

External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.